New combo therapy aims to shrink advanced cervical tumors
NCT ID NCT07080216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two experimental drugs, ZG005 and gecacitinib (with or without bevacizumab), in 120 women with advanced cervical cancer. The goal is to see if the combination is safe and can shrink tumors. Participants must be 18-75 and have a confirmed diagnosis of advanced cervical cancer.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Zhejiang Cancer Hospital
RECRUITINGHangzhou, Zhejiang, 310022, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Can an antiviral make radiation more effective against cervical cancer?
- A One-Two punch against cervical cancer: testing plus vaccination in HIV-Positive women
- Can a Two-Antibody combo outsmart advanced cancer?
- Can robotic surgery match open surgery in beating cervical cancer?
- Blood test clues could sharpen cervical cancer treatment